Company Overview of Q Therapeutics, Inc.
Q Therapeutics, Inc., a clinical-stage company, engages in developing human cell-based therapies intended to treat neurodegenerative diseases of the brain and spinal cord. Its product candidate includes Q-Cells that are healthy human glial progenitor cells intended to restore or preserve normal activity of neurons by providing support functions that occur in healthy central nervous system (CNS) tissues. The company develops Q-Cells for application in a range of CNS diseases, including multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as amyotrophic lateral sclerosis, Huntington’s disease, spinal cord injury, st...
615 Arapeen Drive
Salt Lake City, UT 84108
Key Executives for Q Therapeutics, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Accounting Officer and Vice President of Corporate Development
Scientific Co-Founder, Chief Strategy Officer and Chairman of The Scientific Advisory Board
Vice President of Research & Development
Compensation as of Fiscal Year 2015.
Q Therapeutics, Inc. Key Developments
Q Therapeutics, Inc. Announces Clearance of its Investigational New Drug Application for Phase 1/2A Clinical Trials with Q-Cells in Patients with ALS
Jun 4 15
Q Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for the initiation of Phase 1/2a clinical trials of its Q-Cells product in patients with amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS is a devastating condition caused by degeneration of motor neurons, the nerve cells in the brain and spinal cord that control muscle movement. ALS affects more than 30,000 people in the U.S. at any given time and nearly half a million people worldwide. There is no effective therapy for ALS and it is 80% fatal within five years of diagnosis. Q-Cells, the Company's first patented cellular therapeutic product candidate, are glial-restricted progenitor cells (GRPs) - early descendants of neural stem cells that produce only glia - which make up 50% of cells in the brain. Glia are essential for supporting, maintaining and even restoring neuron health. The FDA's clearance of Q Therapeutics' Investigational New Drug (IND) application for Phase 1/2a clinical trials with Q-Cells in ALS patients confirms that the preclinical data are sufficient to allow initiation of the first-ever human trials evaluating the use of GRPs to treat ALS patients. Published pre-clinical data in animal models of ALS and other central nervous system (CNS) Stained Q-Cell in culture, during differentiation, with yellow showing diseases have demonstrated that delivery of healthy glial cells into the early progenitor characteristics, and red highlighting a protein found brain and spinal cord has the potential to modify the course of currently later in astrocytes, the cell type thought to be beneficial for ALS incurable CNS diseases and injuries.
Q Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Mar 31 15
Q Therapeutics, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Tanner + Co., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Q Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:45 AM
Nov 20 14
Q Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:45 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|